Entasis Therapeutics, INC.
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersWaltham, MA
US patents11
SAM.gov UEIP6NKP5BBSUH3
CAGE code7JD21
Incorporated inDE
Supplier designations
For Profit OrganizationManufacturer of Goods
Self-certified by the company in its SAM.gov registration
Patents
11 US patents granted 2015–2025, 3 of them in the five years to SEP 2025.
Pharmaceuticals 11
- Managing microbial dysbiosis with temocillinUS 12,396,984 · granted AUG 26, 2025
- Compounds and methods for treating bacterial infectionsUS 11,046,694 · granted JUN 29, 2021
- Beta-lactamase inhibitor compoundsUS 10,800,778 · granted OCT 13, 2020
- Combination therapy for treatment of resistant bacterial infectionsUS 10,376,499 · granted AUG 13, 2019
- Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infectionsUS 10,238,661 · granted MAR 26, 2019
Newest 5 shown · Granted to Entasis Therapeutics, Inc. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Entasis Therapeutics, INC. | Waltham | MA | — | LIKELY ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.